Skip to main content

Advertisement

Table 1 Effect of SGLT2 inhibitors combined with ACEI/ARBs

From: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Study Participants Intervention Duration (weeks) Difference amongst groups (95% CI)
HbA1c (%) FPG (mmol/L) SBP (mmHg) Body weight (kg) eGFR (mL/min/1.73 m2) UACR Serum uric acid (μmol/L) Albuminuria
Heerspink [49] A: n = 167 B: n = 189 A: DAPA 10 mg + ACEI/ARB B: ACEI/ARB + PBO 12 A–B: −0.5% (−0.7, −0.3) NR A–B: −3.5 (−5.9, −1.0) A − B: −0.76 (−1.27, −0.26) A–B: −2.80 (−5.43, −0.16) A–B: −23.5% (−37.6, −6.3) NR A–B: −33.2% (−45.4, −18.2)
Weber [50] A: n = 302 B: n = 311 A: DAPA 10 mg + ACEI/ARB B: ACEI/ARB + PBO 12 A–B: −0.49 (−0.59, −0.33) A–B: (−0.69 vs 0.38) A–B: −3.1 (−4.9, −1.2) A–B: (−1.0 vs −0.3) NS NR A–B: (−17.84 vs 5.95) NR
Weber [51] A: n = 225 B: n = 224 A: DAPA 10 mg + ACEI/ARB B: ACEI/ARB + PBO 12 A–B: −0.61% (−0.76, −0.46) A–B: −1.2 (−1.7, −0.8) A–B: −4.28 (−6.54, −2.02) A–B: −0·85 (−1.39, −0.31) NS NS A–B: −23.67 (−33.70, −13.64) NR
Sha [52] A: n = 18 B: n = 18 A: CANA 300 mg + ACEI/ARB + MET B: ACEI/ARB + PBO + MET 12 A–B: −0.6% (−0.9, −0.3) A–B: −1.6 (−2.3, −0.9) A–B: −13.3 (−21.2, −5.3) (supine SBP) A–B: −16.2 (−24.9, −7.5) (standing SBP) A–B: −3.5 (−4.2, −2.7) A–B: −4.0 (−8.7, 0.7) NR NR NR
  1. Data reported as placebo-adjusted difference (95% CI) or adjusted mean change from baseline (A group vs B group)
  2. SGLT2 Sodium–glucose co-transporter 2, ACEI/ARBs angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 95% CI 95% confidence interval, HbA1c glycated haemoglobin, FPG fasting plasma glucose, SBP systolic blood pressure, eGFR estimated glomerular filtration rate, UACR urinary albumin creatinine ratio, DNPA dapagliflozin, PBO placebo, NR not reported/retrievable, vs versus, NS not-significant, CANA canagliflozin, MET metformin